
Leading diagnostic solutions company Quidel Corporation (QDEL) in San Diego, Calif., delivers a continuum of rapid testing technologies to improve the quality of health care worldwide. The company pioneered the first point-of-care influenza test in 1999 and was the first to offer a rapid SARS-CoV-2 antigen test in the United States.
However, the stock has declined 59.5% in price over the past year and 35.7% over the past three months to close yesterday's trading session at $95.39. In addition, it is currently trading below its 50-day and 200-day moving averages of $123.05 and $128.07, respectively, indicating a downtrend.